ArticleCancer management and research2019

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial.

Xing-Sheng Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.